Development of KGF Antagonist as a Breast Cancer Therapeutic
Abstract
Our recent findings suggest that keratinocyte growth factor (KGF), the seventh member of the fibroblast growth factor family, is capable of acting as a mediator of the stimulatory effects of estrogen in human breast cancer cells. Interestingly, estrogen stimulates KGF expression. This role of estrogens in the regulation of KGF expression is intriguing because hormonal stimulation is an essential factor in the carcinogenesis of human breast cells, especially during early stages. Therefore, it is possible that KGF could be intimately involved in both physiological and pathological processes in human breast tissue. Thus, the ability to interrupt the stimulatory effects of estrogen in human breast cancer cells at the level of KGF holds potential value as a strategy for development of as a potential therapeutic agent for breast cancer. Consequently, we have proposed to synthesize potential KGF antagonists, which will then be evaluated for efficacy in vitro assay systems. During the first year of this funding period, we have concentrated in peptide antagonist synthesis and development of an assay system. There were unexpected difficulties on the peptide syntheses, however, we have hound a way to syntheses those peptides.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA388578
Entities
People
- Yasuro Sugimoto
Organizations
- Ohio State University